Fair Value Measurements - Roll Forward of Changes in Fair Value of Financial Liabilities Classified as Level 3 (Details) - Level 3 [Member] $ in Thousands |
9 Months Ended |
|---|---|
|
Sep. 30, 2026
USD ($)
| |
| Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] | |
| Beginning balance at December 31, 2025 | $ 0 |
| Contingent Consideration Liabilities recognized upon acquisition of Mantle Therapeutics Inc. on September 29, 2026 | 1,267 |
| Change in estimated fair value since acquisition | 0 |
| Ending balance at September 30, 2026 | $ 1,267 |
| X | ||||||||||
- Definition Fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, change in estimated fair value. No definition available.
|
| X | ||||||||||
- Definition Fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, contingent consideration liabilities. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|